Scholarlink

<p>Iptacopan (Fabhalta<sup>®</sup>), a complement factor B inhibitor, is a valuable treatment option for adult patients with paroxysmal nocturnal haemoglobinuria (PNH). It is the first oral monotherapy available for treatment of PNH in the USA and the EU. As demonstrated in the phase III clinical trials APPLY-PNH and APPOINT-PNH, twice daily iptacopan provided clinically meaningful improvements in haemoglobin levels in both anti-complement component 5 (anti-C5) therapy-experienced and complement inhibitor-naïve patients with PNH and anaemia. In APPLY-PNH, iptacopan was superior to continuing anti-C5 therapy at improving haemoglobin levels without the need for red blood cell transfusions (RBCTs). In both trials, iptacopan also reduced the need for RBCTs and reduced patient-reported fatigue levels. Iptacopan was generally well tolerated, with the most common adverse events being acute mild-to-moderate headache and with no discontinuations due to adverse events recorded in either trial. Currently available data show iptacopan efficacy is durable over 48 weeks; longer term efficacy and safety data are awaited with interest.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Iptacopan in paroxysmal nocturnal haemoglobinuria: a profile of its use

  • 期刊论文

  • 发表日期：

    2025年3月26日

查看全文
  • Michael B. Brown,
  • Matt Shirley

摘要

Iptacopan (Fabhalta®), a complement factor B inhibitor, is a valuable treatment option for adult patients with paroxysmal nocturnal haemoglobinuria (PNH). It is the first oral monotherapy available for treatment of PNH in the USA and the EU. As demonstrated in the phase III clinical trials APPLY-PNH and APPOINT-PNH, twice daily iptacopan provided clinically meaningful improvements in haemoglobin levels in both anti-complement component 5 (anti-C5) therapy-experienced and complement inhibitor-naïve patients with PNH and anaemia. In APPLY-PNH, iptacopan was superior to continuing anti-C5 therapy at improving haemoglobin levels without the need for red blood cell transfusions (RBCTs). In both trials, iptacopan also reduced the need for RBCTs and reduced patient-reported fatigue levels. Iptacopan was generally well tolerated, with the most common adverse events being acute mild-to-moderate headache and with no discontinuations due to adverse events recorded in either trial. Currently available data show iptacopan efficacy is durable over 48 weeks; longer term efficacy and safety data are awaited with interest.